Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

VSA Morning Technology Comment, 20/05/21 Frontier IP Group (LON:FIPP) Portfolio Company Exscientia announces multi-target, AI-driven drug discovery collaboration with Bristol Myers Squibb Frontier IP Group yesterday announced that UK based portfolio company Exscientia Limited ("Exscientia"), had entered into a collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY). Exscientia uses AI across its platform from target identification through drug design and patient selection in order to precision engineer new medicines.

VSA Capital Market Movers - Frontier IP Group

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO21--Four-Year Data from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo Plus Yervoy in Patients with NSCLC.....

Four-Year Data from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Patients with Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO21--Opdivo + Yervoy with Two Cycles of Chemotherapy Demonstrates Durable Overall Survival vs. Chemotherapy at Two Years in First-Line NSCLC.....

Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy Demonstrates Durable Overall Survival vs. Chemotherapy at Two Years in First-Line Non-Small Cell Lung Cancer in Phase 3 CheckMate -9LA Trial

PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BMY #ASCO21--Long-Term Data from Pivotal KarMMa Study Continue to Demonstrate Deep and Durable Responses and Predictable Safety Profile with Abecma.....

Long-Term Data from Pivotal KarMMa Study Continue to Demonstrate Deep and Durable Responses and Predictable Safety Profile with Bristol Myers Squibb and bluebird bio's Abecma (idecabtagene vicleucel) in Relapsed or Refractory Multiple Myeloma

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO21--Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival.....

Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO21--BMS Announces LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination Significantly Improves Progression-Free Survival vs. Opdivo.....

Bristol Myers Squibb Announces LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination Significantly Improves Progression-Free Survival vs. Opdivo (nivolumab) in Patients with Previously Untreated Metastatic or Unresectable Melanoma

Alkermes

Biogen

Blueprint Medicines

Myovant Sciences

Provention Bio Inc

Sanofi

Vertex Pharmaceuticals

Biotech stocks frequently make big moves on a single trial result or FDA ruling. These 8 drugmakers are worth watching amid important events on deck this summer.

8 Biotech Stocks With Major Catalysts on the Horizon

Agenus

Bristol-Myers (BMY) obtains exclusive license for Agenus' antibody program, AGEN1777, for an upfront payment of $200 million and up to $1.36 billion in milestone payments.

Bristol-Myers (BMY) Teams Up With Agenus for Antibody Program

Agenus (AGEN) inks a definitive agreement with Bristol-Myers, wherein it will grant license to its bispecific antibody program AGEN1777 and another undisclosed target, to the latter.

Agenus (AGEN) Soars on Global License Deal With Bristol-Myers

Privately-held Exscientia has expanded its collaboration agreement with Bristol-Myers Squibb Co (NYSE: BMY) that builds upon Exscientia's existing collaboration initiated in 2019 with Celgene, before Bristol-Myers acquisition. The collaboration will use AI to accelerate the discovery of small molecule therapeutic drug candidates in multiple therapeutic areas, including oncology & immunology.

Exscientia, Bristol Myers Expand AI Based Drug Discovery Collaboration With Potential Milestones Over $1.2B

Kellogg

Altria

Southern Company

Verizon

Tuesday's big reversal should remind investors that some of the current realities, while not totally baked in as certainties, really need to be considered when portfolio planning for the rest of 2021.

Top Wall Street Strategist Says Buy Defensive Dividend Growth for the Rest of 2021

CLEVELAND--(BUSINESS WIRE)-- #celltherapy--Blue Spark Technologies, Inc. today announced that Bristol Myers Squibb (BMS, NYSE: BMY) will use its TempTraq wearable Bluetooth continuous body temperature monitoring platform in a U.S. observational trial to monitor patients across multiple BMS CAR T assets prior to and following CAR T patients' infusion with the cell therapy. This observational trial will be Bristol Myers Squibb's first use of a remote patient monitoring technology to track CAR T patient temperat

Blue Spark Technologies Announces Observational Trial Using TempTraq® Wearable Device in CAR T Patient Monitoring

OXFORD, England--(BUSINESS WIRE)--Exscientia, the clinical stage, Artificial Intelligence (AI)-driven pharmatech company, announced today that it has entered into a collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY). This expanded collaboration has the potential to add to the Bristol Myers Squibb drug pipeline whilst enhancing Exscientia's portfolio of shared assets. The collaboration will use AI to accelerate the discovery of small molecule therapeutic drug candidates in mul

Exscientia announces multi-target, AI-driven drug discovery collaboration with Bristol Myers Squibb

Chevron

Merck

Wells Fargo

Warren Buffett's Berkshire Hathaway cut back on financial, energy and drug stocks but beefed up his grocery and wireless holdings while adding an insurer.

Warren Buffett's Berkshire Hathaway shakes up investment holdings

Booking Hlds

Old Dominion Freight Line

Progressive

PayPal

Tapestry

Visa

Wedgewood Partners Chief Investment Officer David Rolfe (Trades, Portfolio) disclosed his portfolio for the first quarter of 2021 earlier this week.

David Rolfe's Top 6 Trades of the 1st Quarter

Bristol-Myers Squibb Co (NYSE: BMY) and Agenus Inc (NASDAQ: AGEN) have entered into a global exclusive license agreement, under which Bristol Myers will receive an exclusive license to Agenus' AGEN1777 and a second undisclosed target. Bristol Myers Squibb will become solely responsible for the development and subsequent commercialization of AGEN1777 and its related products worldwide.

Bristol Myers Inks $1.6B Licensing Agreement For Agenus' Bispecific Antibody Program In Solid Tumors

NEW YORK & LEXINGTON, Mass.--(BUSINESS WIRE)---- $BMY--Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus' Anti-TIGIT Bispecific Antibody Program

Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus' Anti-TIGIT Bispecific Antibody Program

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb to Take Part in UBS Global Healthcare Virtual Conference

Bristol Myers Squibb to Take Part in UBS Global Healthcare Virtual Conference

Bristol Myers (BMY) announces new positive data on mavacamten from a late-stage study at the American College of Cardiology's 70th Annual Scientific Session.

Bristol Myers (BMY) Announces New Data on Cardiovascular Candidate

Broadcom

Enbridge

The markets got jittery on inflation data and dropped. If you're worried every time the market moves, maybe you need to change your approach.

Buy Alert: 3 All-Weather Bargains For When The Market Gets Scared

Amazon

Microsoft

Long-term investors stand to benefit significantly from these three stocks in a reopening economy.

The 3 Smartest Stocks to Buy in a Reopening Economy

Bristol Myers Squibb Co (NYSE: BMY) announced a new analysis of data from the Phase 3 EXPLORER-HCM study evaluating mavacamten in patients with obstructive hypertrophic cardiomyopathy (oHCM). New data were presented at the American College of Cardiology Annual Scientific Session, with simultaneous publication in The Lancet.

Bristol Myers Unveils More Mavacamten Data To Backup Case For Heart Drug

Pfizer

Pfizer Inc (NYSE: PFE) and Bristol Myers Squibb Co (NYSE: BMY) partnered Eliquis (apixaban) failed to show benefit over standard of care in preventing serious clinical outcomes after a transaortic valve replacement (TAVR), according to the data from a new trial called Atlantis presented at the virtual American College of Cardiology meeting. The drug was linked to an “unexplained signal” in a subset of populations with a higher rate of non-cardiovascular deaths which did not need blood thinners apart from the surgery.

Pfizer-Bristol Myers' Eliquis Flops In Post-Heart Surgery Trial

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACC21--BMS Presents Late-Breaking Phase 3 Data Demonstrating Health Status Benefits of Mavacamten in Patients with oHCM at #ACC21

Bristol Myers Squibb Presents Late-Breaking Phase 3 Data Demonstrating Health Status Benefits of Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy at American College of Cardiology's 70th Annual Scientific Session

DraftKings

PACCAR

Skillz

Twitter

ARK Investment, the asset management firm founded by Catherine Wood (Trades, Portfolio), disclosed this week that its top five new positions during the first quarter were in Twitter Inc. ( TWTR , Financial), PACCAR Inc. ( PCAR , Financial), DraftKings Inc. ( DKNG , Financial), Bristol-Myers Squibb Co. ( BMY , Financial) and Skillz Inc. ( SKLZ , Financial).

News for Bristol-Myers Stock (BMY)